When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19.

The coronavirus disease 2019 (COVID-19) continues to wreak havoc, culminating in soaring morbidity and mortality worldwide. To date, a plethora of pharmaceutical regimens has been employed in the treatment of the infection, but management of the ailment still remains largely supportive. In addition to antivirals such as remdesivir, azithromycin and tocilizumab also remain the cornerstone of current therapeutic management. Recent research has divulged that the exorbitantly high fatality and morbidity rates associated with COVID-19 can be attributed, in part, to an aberrant and dysregulated immune response that ensues secondary to the cytokine storm observed in COVID-19 [1]. Corticosteroids have traditionally remained exceedingly imperative in the management of hyperinflammatory states. Owing to their potent anti-inflammatory properties, corticosteroids have remained at the epicentre of a therapeutic conundrum surrounding the optimal management of COVID-19.